InvestorWire NewsRoom

Article

Brain Scientific Inc.’s (BRSF) Technology Could Be Part of the Solution as New Research Finds that Neurological Consequences of COVID-19 Could be the Norm Rather than Exception
August 17, 2021

Brain Scientific Inc.’s (BRSF) Technology Could Be Part of the Solution as New Research Finds that Neurological Consequences of COVID-19 Could be the Norm Rather than Exception

  • It has become known that COVID-19 patients can present with neurological symptoms, but new comprehensive cross-country study indicates that it could be more prevalent than previously thought
  • This could represent enormous challenge to healthcare as it needs to prepare for immediate and longer-term rehabilitation care of these patients
  • Brain Scientific is committed to remaining at forefront of brain diagnostics, potentially offering solution to higher need for neurological care of COVID-19 patients

Brain Scientific (OTCQB: BRSF), a commercial-stage health care company on a mission to modernize brain diagnostics, could be the one offering solution to the rising challenge global healthcare systems face in the post-Covid world. As scientists are starting to collect more and more data, they can decipher both immediate and longer-term consequences of SARS-CoV-2 infection. Research has been mounting demonstrating that some infected patients suffer from neurological symptoms, including memory loss, stroke, and other effects on the brain (https://ibn.fm/CM7uW). However, the new comprehensive cross-country study recently published in the Journal of Neurology, Neurosurgery, and Psychiatry reveals that neurological symptoms may actually be the norm rather than an exception (https://ibn.fm/s3uJw).

A new systematic review and meta-analysis conducted by University College London examined 215 COVID-19 studies across 30 different countries involving 105,638 symptomatic COVID-19 patients from January to July 2020. The research team was expecting to find neurologic and psychiatric findings to be more common in severe COVID-19. Instead, they found that some of these symptoms appeared to be more common in mild cases, indicating that COVID-19 affecting the brain could be the norm, rather than the exception as previously thought. 

The study also demonstrates no clear link of these symptoms to systemic or respiratory symptoms. According to the authors, the most prevalent neurological symptoms actually occurred more frequently in patients with less severe COVID-19. This finding could indicate that neurological symptoms are not necessarily correlated with systemic or respiratory symptoms.

As we learn more about COVID-19, it is becoming increasingly clear that neurological care in the post-Covid world will be crucial. In the words of the authors, with millions of people infected globally, even the rarer symptoms could affect considerably more people than in normal times. Due to the sheer scale of the pandemic, this could potentially represent a massive challenge to healthcare systems that need to prepare both for the immediate care of these patients and their longer-term rehabilitation needs. In an environment like this, Brain Scientific’s next-generation technological solutions for the neurology market could become critical as they offer EEG testing to be deployed rapidly and accurately in children and adults alike. The company’s two FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM), allow quick and reliable EEG testing in minutes and by any healthcare worker, not only specialized neurological technicians, bringing brain diagnostics to settings where it was previously impossible or difficult to conduct neurological testing. 

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).